Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
Journal article published in 2021 by
Sosana Delimpasi 
,
Maria Victoria Mateos,
Holger W. Auner ,
Maria Gavriatopoulou ,
Meletios A. Dimopoulos ,
Hang Quach,
Halyna Pylypenko,
Roman Hájek,
Xavier Leleu,
Tuphan Kanti Dolai,
Dinesh Kumar Sinha,
Christopher P. Venner ,
Reuben Benjamin ,
Mamta Krishnan Garg,
Vadim Doronin
and other authors.
,
Maria Victoria Mateos,
Holger W. Auner ,
Maria Gavriatopoulou ,
Meletios A. Dimopoulos ,
Hang Quach,
Halyna Pylypenko,
Roman Hájek,
Xavier Leleu,
Tuphan Kanti Dolai,
Dinesh Kumar Sinha,
Christopher P. Venner ,
Reuben Benjamin ,
Mamta Krishnan Garg,
Vadim Doronin
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 